{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:58:26Z","timestamp":1781647106261,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.trim.2025.102297","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:54:58Z","timestamp":1758063298000},"page":"102297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["De novo donor specific antibody (dnDSA) development with tacrolimus versus Belatacept based regimens in kidney transplant recipients"],"prefix":"10.1016","volume":"93","author":[{"given":"Cayla","family":"Kass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goni","family":"Katz-Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bodner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Sanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaattin","family":"Erkanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Byrns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2025.102297_bb0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"Special issue: KDIGO clinical practice guideline for the Care of Kidney Transplant Recipients","volume":"9","author":"Eckardt","year":"2009","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.trim.2025.102297_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5500\/wjt.v2.i4.51","article-title":"Current state of renal transplant immunosuppression: present and future","volume":"2","author":"Kalluri","year":"2012","journal-title":"World J. Transplant."},{"issue":"7520","key":"10.1016\/j.trim.2025.102297_bb0015","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.trim.2025.102297_bb0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.trim.2025.102297_bb0025","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.trim.2025.102297_bb0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","article-title":"Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft REJECTION1","volume":"64","author":"Mayer","year":"1997","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.trim.2025.102297_bb0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4103\/0976-500X.92499","article-title":"Belatacept: a worthy alternative to cyclosporine?","volume":"3","author":"Melvin","year":"2012","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"3","key":"10.1016\/j.trim.2025.102297_bb0040","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of Belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.trim.2025.102297_bb0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.trim.2025.102297_bb0050","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.TP.0000055833.65192.3B","article-title":"Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome1","volume":"75","author":"Worthington","year":"2003","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.trim.2025.102297_bb0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2215\/CJN.00700117","article-title":"Donor-specific antibodies in kidney transplant recipients","volume":"13","author":"Zhang","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.trim.2025.102297_bb0060","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/ajt.15754","article-title":"Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients","volume":"20","author":"Wan","year":"2020","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.trim.2025.102297_bb0065","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies","volume":"74","author":"Lee","year":"2002","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.trim.2025.102297_bb0070","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1600-6143.2009.02800.x","article-title":"De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure","volume":"9","author":"Hidalgo","year":"2009","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2025.102297_bb0075","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2025.102297_bb0080","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell\u2013 and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am. J. Transplant."},{"issue":"7","key":"10.1016\/j.trim.2025.102297_bb0085","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies","volume":"18","author":"Bray","year":"2018","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.trim.2025.102297_bb0090","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1111\/ajt.16121","article-title":"Kidney transplantation using alemtuzumab, belatacept, and sirolimus: five-year follow-up","volume":"20","author":"Schmitz","year":"2020","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.trim.2025.102297_bb0095","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/ajt.13469","article-title":"Postdepletion lymphocyte reconstitution during Belatacept and rapamycin treatment in kidney transplant recipients","volume":"16","author":"Xu","year":"2016","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2025.102297_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13042","article-title":"Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: a single-center clinical experience","volume":"31","author":"Wojciechowski","year":"2017","journal-title":"Clin. Transpl."},{"issue":"9S","key":"10.1016\/j.trim.2025.102297_bb0105","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1097\/01.tp.0000886116.05704.01","article-title":"245.4: Belatacept vs. tacrolimus in the real world: an efficacy and safety analysis","volume":"106","author":"Arazo","year":"2022","journal-title":"Transplantation"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632742500125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632742500125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:14:34Z","timestamp":1765055674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096632742500125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"alternative-id":["S096632742500125X"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2025.102297","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De novo donor specific antibody (dnDSA) development with tacrolimus versus Belatacept based regimens in kidney transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2025.102297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102297"}}